News Sanofi/Lexicon's sotagliflozin filed in US and EU for type 1... Regulators in the US and Europe are to review Sanofi/Lexicon’s sotagliflozin in type 1 diabetes, a potential blockbuster pill.
News Ablynx drug fails in mid-stage lupus trial Ablynx’s vobarilizumab has failed in a mid-stage trial in lupus, with the biotech’s multi-billion buyout from Sanofi just around the corner.
Partner Content Partner Content Sanofi Joins the Speaker Line-up for SMi's Launch, Injectabl... Injectable Drug Delivery
News Sanofi passes on Alnylam's breakthrough therapy Alnylam is to forge ahead with a rare disease therapy on its own after Sanofi decided to opt out of a co-development and co-marketing deal.
News Double blow to Amgen with Sanofi's Praluent data and price c... Sanofi and Regeneron have scored a major victory in their fight with Amgen in the market for cardiovascular drugs, after releasing data showing their Praluent injection reduces risk of card
News Court sides with EU on decision to revoke Ocaliva's license Advanz Pharma's bid to keep its Ocaliva treatment for rare liver disease primary biliary cholangitis (PBC) on the EU market has ended in failure
Sales & Marketing Coming soon: The Life Sciences Industry Report 2025 – insigh... Prepare for 2025 with pharmaphorum’s Life Sciences Report, featuring expert insights on AI in drug development, gene therapy, and top industry trends
